TY - JOUR
T1 - New Uses for a New Oil
T2 - Clinical Applications of Fish Oil Lipid Emulsion
AU - Mohamed Elfadil, Osman
AU - Bonnes, Sara L.
AU - Salonen, Bradley R.
AU - Vellapati, Saketh
AU - Patel, Janki
AU - Narasimhan, Ramya
AU - Hurt, Ryan T.
AU - Mundi, Manpreet S.
N1 - Funding Information:
Ryan T. Hurt is a consultant for Nestle. Manpreet S. Mundi has an unrestricted investigator-initiated research grant from Fresenius Kabi, Nestle, and Realfood blends and is a consultant for Baxter. Osman Mohamed Elfadil, Saketh Vellapati, Janki Patel, Ramya Narasimhan, Sara L. Bonnes, and Bradley R. Salonen have no financial disclosure or conflict of interest to report.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose of Review: Parenteral nutrition (PN) has been utilized as an essential therapeutic tool in healthcare for more than 5 decades. In United States, the prevalence of home parenteral nutrition (HPN) is estimated to be more than 25,000 patients. Intravenous lipids emulsions (ILEs) are a critically important component of PN as a source of calories and essential fatty acids. In order to provide a deeper understanding of the benefits and risks associated with use of fish oil (FO) containing ILE, this manuscript reviews the history of ILE development, unique benefits of FO, and the clinical data available for FO containing ILEs. Recent Findings: Over the years, major developments have occurred in order to achieve a nontoxic and stable emulsion. Extensive research and product development led to the development of multiple generations of ILEs. FO containing ILEs, the latest ILE generation, were introduced as safe, effective, and beneficial emulsions with distinct properties and mechanisms of action. Summary: In this review, we describe ILEs development milestones, biological and metabolic benefits of FO containing ILEs, and key clinical outcome data with consensus key remarks as well as highlighting the challenges in clinical applications and gaps in literature.
AB - Purpose of Review: Parenteral nutrition (PN) has been utilized as an essential therapeutic tool in healthcare for more than 5 decades. In United States, the prevalence of home parenteral nutrition (HPN) is estimated to be more than 25,000 patients. Intravenous lipids emulsions (ILEs) are a critically important component of PN as a source of calories and essential fatty acids. In order to provide a deeper understanding of the benefits and risks associated with use of fish oil (FO) containing ILE, this manuscript reviews the history of ILE development, unique benefits of FO, and the clinical data available for FO containing ILEs. Recent Findings: Over the years, major developments have occurred in order to achieve a nontoxic and stable emulsion. Extensive research and product development led to the development of multiple generations of ILEs. FO containing ILEs, the latest ILE generation, were introduced as safe, effective, and beneficial emulsions with distinct properties and mechanisms of action. Summary: In this review, we describe ILEs development milestones, biological and metabolic benefits of FO containing ILEs, and key clinical outcome data with consensus key remarks as well as highlighting the challenges in clinical applications and gaps in literature.
KW - Fish oil
KW - Intravenous lipid emulsions
KW - Lipids
KW - Parenteral nutrition
UR - http://www.scopus.com/inward/record.url?scp=85086714565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086714565&partnerID=8YFLogxK
U2 - 10.1007/s40137-020-00259-1
DO - 10.1007/s40137-020-00259-1
M3 - Review article
AN - SCOPUS:85086714565
SN - 2167-4817
VL - 8
JO - Current Surgery Reports
JF - Current Surgery Reports
IS - 8
M1 - 16
ER -